NCT02922543View on ClinicalTrials.gov

A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use

CompletedOBSERVATIONAL

Enrollment

361

Participants

Timeline

Start Date

February 18, 2011

Primary Completion Date

October 11, 2014

Study Completion Date

October 11, 2014

Conditions

Multiple Myeloma

Trial Locations (1)

651-0072

Shinko Hospital, Kobe

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Celgene

INDUSTRY